

**CHAPTER 8****COLLECTION, PROCESSING, STORAGE AND  
DISTRIBUTION OF BLOOD****Authority**

N.J.S.A. 26:1A-7 and 26:2A-7; and Reorganization Plan No. 003-2005.

**Source and Effective Date**

R.2011 d.056, effective January 19, 2011.  
See: 42 N.J.R. 1771(a), 43 N.J.R. 401(a).

**Chapter Expiration Date**

Chapter 8, Collection, Processing, Storage and Distribution of Blood, expires on January 19, 2016.

**Chapter Historical Note**

Chapter 8, Collection, Processing, Storage and Distribution of Blood, was filed and became effective prior to September 1, 1969.

Pursuant to Executive Order No. 66(1978), Chapter 8, Collection, Processing, Storage and Distribution of Blood, was readopted as R.1989 d.246, effective April 12, 1989. See: 21 N.J.R. 407(a), 21 N.J.R. 1412(a).

Pursuant to Executive Order No. 66(1978), Chapter 8, Collection, Processing, Storage and Distribution of Blood, was readopted as R.1994 d.229, effective April 12, 1994. See: 26 N.J.R. 1057(a), 26 N.J.R. 2025(a). Pursuant to Executive Order No. 66(1978), Chapter 8 expired on April 12, 1999.

Chapter 8, Collection, Processing, Storage and Distribution of Blood, was adopted as new rules by R.1999 d.288, effective August 16, 1999. See: 31 N.J.R. 947(a), 31 N.J.R. 2373(c).

Chapter 8, Collection, Processing, Storage and Distribution of Blood, expiration date was extended by gubernatorial directive from February 12, 2005 to February 12, 2006, in accordance with N.J.S.A. 52:14B-5.1d. See: 37 N.J.R. 774(a).

Chapter 8, Collection, Processing, Storage and Distribution of Blood, was readopted as R.2005 d.283, effective August 1, 2005. See: 36 N.J.R. 4261(a), 37 N.J.R. 3815(a).

Subchapter 13, Hematopoietic Progenitor Cells, was adopted as new rules by R.2005 d.283, effective October 3, 2005. See: 36 N.J.R. 4261(a), 37 N.J.R. 3815(a).

Appendices A and B were adopted as new rules by R.2008 d.352, effective November 17, 2008. See: 40 N.J.R. 1951(a), 40 N.J.R. 6605(a).

Chapter 8, Collection, Processing, Storage and Distribution of Blood, was readopted as R.2011 d.056, effective January 19, 2011. See: Source and Effective Date.

**CHAPTER TABLE OF CONTENTS****SUBCHAPTER 1. GENERAL PROVISIONS**

- 8:8-1.1 Compliance
- 8:8-1.2 Definitions
- 8:8-1.3 Licensure
- 8:8-1.4 Inspection
- 8:8-1.5 Proficiency testing
- 8:8-1.6 Brokers
- 8:8-1.7 Waivers
- 8:8-1.8 Public Health Council

**SUBCHAPTER 2. PERSONNEL**

- 8:8-2.1 General
- 8:8-2.2 Blood bank director
- 8:8-2.3 Blood bank personnel

**SUBCHAPTER 3. FACILITIES, EQUIPMENT AND  
CONTAMINATED MATERIAL**

- 8:8-3.1 Facilities and equipment
- 8:8-3.2 Contaminated material

**SUBCHAPTER 4. MANAGEMENT**

- 8:8-4.1 Quality control and quality assurance
- 8:8-4.2 Standard operating procedures
- 8:8-4.3 Documented review
- 8:8-4.4 Errors and accidents

**SUBCHAPTER 5. RECORDS AND REPORTING  
REQUIREMENTS**

- 8:8-5.1 Records
- 8:8-5.2 Reporting requirements
- 8:8-5.3 through 8:8-5.5 (Reserved)

**SUBCHAPTER 6. CRITERIA FOR DONOR SELECTION**

- 8:8-6.1 Donor identification
- 8:8-6.2 Medical history; physical examinations; bleeding limitations
- 8:8-6.3 Donor selection; deferral records; deferral notice to donor
- 8:8-6.4 Information provided to the donor
- 8:8-6.5 AIDS screening requirements

**SUBCHAPTER 7. BLOOD AND BLOOD COMPONENTS**

- 8:8-7.1 General criteria
- 8:8-7.2 Testing
- 8:8-7.3 through 8:8-7.14 (Reserved)

**SUBCHAPTER 8. COLLECTION OF BLOOD**

- 8:8-8.1 General criteria
- 8:8-8.2 Donor emergency care
- 8:8-8.3 Medical contingency plan
- 8:8-8.4 Donor protection
- 8:8-8.5 Method of blood and blood component collection
- 8:8-8.6 Pilot samples
- 8:8-8.7 Blood containers
- 8:8-8.8 Labeling
- 8:8-8.9 Sterility testing
- 8:8-8.10 Autologous collection/transfusion
- 8:8-8.11 Directed donation
- 8:8-8.12 Perioperative autologous blood collection and administration
- 8:8-8.13 Therapeutic phlebotomy
- 8:8-8.14 Plasmapheresis
- 8:8-8.15 Cytapheresis
- 8:8-8.16 Immunized donor

**SUBCHAPTER 9. RECIPIENT BLOOD TESTING**

- 8:8-9.1 General provisions
- 8:8-9.2 Suspected transfusion reactions
- 8:8-9.3 Operative blood order schedules
- 8:8-9.4 Urgent requirement for blood and blood components

**SUBCHAPTER 10. ISSUE AND ADMINISTRATION OF  
BLOOD AND BLOOD COMPONENTS FOR  
TRANSFUSION**

- 8:8-10.1 Issue of blood
- 8:8-10.2 Administration of blood and blood components
- 8:8-10.3 Reissue of blood and blood components
- 8:8-10.4 through 8:8-10.7 (Reserved)

**SUBCHAPTER 11. STORAGE OF BLOOD**

- 8:8-11.1 General provisions
- 8:8-11.2 Refrigerators for the storage of blood and blood components

- 8:8-11.3 Freezers for the storage of blood and blood components
- 8:8-11.4 Room temperature storage
- 8:8-11.5 Temperature monitoring systems
- 8:8-11.6 Inspection of stored blood and blood components
- 8:8-11.7 Expiration dates of blood and blood components
- 8:8-11.8 Packaging and transportation

## SUBCHAPTER 12. OUT-OF-HOSPITAL TRANSFUSIONS

- 8:8-12.1 General provisions
- 8:8-12.2 Out-of-hospital transfusions (OOHT)
- 8:8-12.3 Out-of-hospital transfusions (OOHT) in emergency situations

## SUBCHAPTER 13. HEMATOPOIETIC PROGENITOR CELLS

- 8:8-13.1 Compliance
- 8:8-13.2 Definitions
- 8:8-13.3 Personnel
- 8:8-13.4 Quality management
- 8:8-13.5 Records
- 8:8-13.6 Reporting requirements
- 8:8-13.7 Criteria for donor identification
- 8:8-13.8 Criteria for donor selection
- 8:8-13.9 Collection of HPC
- 8:8-13.10 Collection of cord blood
- 8:8-13.11 Processing
- 8:8-13.12 Cryopreservation
- 8:8-13.13 Testing of donors
- 8:8-13.14 Labeling
- 8:8-13.15 Expiration dates
- 8:8-13.16 Storage
- 8:8-13.17 Issue
- 8:8-13.18 Reissue
- 8:8-13.19 Packaging and transportation
- 8:8-13.20 Administration

## APPENDIX A

## APPENDIX B

## SUBCHAPTER 1. GENERAL PROVISIONS

### 8:8-1.1 Compliance

(a) Persons, known as licensees, for the purpose of this chapter, shall operate blood banks in this State and shall meet the qualifications and conduct blood banks in accordance with N.J.S.A. 26:2A-2 et seq. and all rules in this chapter.

(b) Failure to comply with N.J.S.A. 26:2A-2 et seq. and with this chapter shall be cause for revocation of license and imposition of penalties as prescribed by N.J.S.A. 26:2A-2 et seq.

Amended by R.1994 d.350, effective August 1, 1994.  
See: 26 N.J.R. 1057(a), 26 N.J.R. 3171(a).  
Amended by R.2005 d.283, effective October 3, 2005.  
See: 36 N.J.R. 4261(a), 37 N.J.R. 3815(a).  
Rewrote (a).

### 8:8-1.2 Definitions

For the purpose of this chapter, the terms listed below shall be defined and interpreted as follows:

“AABB Standards” means the “Standards for Blood Banks and Transfusion Services,” 23rd Edition (2004), incorporated herein by reference as amended and supplemented and the “Standards for Cellular Therapy Product Services,” First Edition (2004), incorporated herein by reference as amended and supplemented, both of which publications are published by the American Association of Blood Banks, 8101 Glenbrook Road, Bethesda, MD 20814-2749, (301) 907-6977, [www.aabb.org](http://www.aabb.org).

“Accident” means a non-preventable occurrence.

“Additive solution system” means blood preservative systems designed primarily for the extended storage of red blood cells. These systems utilize a second preservative solution for red cell storage in addition to the anticoagulant solution necessary for whole blood collection.

“Allogeneic” means the collection of blood or blood components for subsequent transfusion to an individual other than the donor. The term “allogeneic” is also known as homologous.

“Autologous donation/transfusion” means the collection of blood and blood components from a donor/recipient for subsequent reinfusion into the same individual. The term “autologous” is also known as autogeneic.

“Blood bank” means any commercial or noncommercial activity involving the handling of blood or plasma, intended to be used for therapeutic or prophylactic purposes, which participates in any of the following operations: collection, processing, storage, distribution or administration of blood.

“Blood components” means those preparations that are separated from whole blood and are intended for use as final products for therapeutic purposes, for further manufacturing, or as products used for in vitro testing.

“Broker” means procuring, selling and distributing of blood, blood components or blood products without engaging in processing, alteration or other manipulation of the blood component.

“Center for Biologics Evaluation and Research (CBER)” means the U.S. Food and Drug Administration (FDA), Department of Health and Human Services.

“Clinical practitioner” means a physician currently licensed to practice in New Jersey; an advanced practice nurse currently certified under the New Jersey Advanced Practice Nurse Certification Act; or a physician assistant licensed under the Physician Assistant Licensing Act, acting within the rules governing those professions. Where authorized under this chapter, clinical practitioners shall be permitted to order transfusions and procedures related to the collection or donation of blood and blood products. Advanced practice nurses shall order only according to specific written joint protocols established with the collaborating physician and